# Elecsys pTau217 is the first blood test designed to signal and rule out Alzheimer's disease.

*biotech · news · 2026-05-12 · Euronews*

## Key points

- Elecsys pTau217 is the first blood test cleared in Europe to rule out Alzheimer's disease.
- The test received CE Mark approval, allowing its use throughout the European Union.
- Elecsys pTau217 detects high pTau217 protein levels, indicating likely presence of amyloid plaques.
- A negative result can spare patients from invasive tests like spinal fluid analysis or brain scans.
- The test enables earlier Alzheimer's diagnosis in both primary and secondary care settings.

**Companies:** Roche, Eli Lilly and Company
**Countries:** Switzerland, European Union

[Read the full story on Euronews](https://www.euronews.com/health/2026/05/12/roche-gets-european-approval-for-alzheimers-diagnosis-blood-test)

---

Canonical: https://newsio.io/n/746c17cf-a84e-409d-bba8-09bca8bf7d61/elecsys-ptau217-is-the-first-blood-test-designed-to-signal-and-rule-out-alzheime
Summarized by Newsio from Euronews. https://newsio.io/how-it-works